Skip to content

Comparison of clinical efficacy of LC+LCBDE+ENBD and LC+LCBDE+T-tube in the treatment of choledocholithiasis

hepatobiliary and pancreatic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066630
Enrollment
Unknown
Registered
2022-12-12
Start date
2022-12-15
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

choledocholithiasis

Interventions

Control group:LC+LCBDE+ENBD operation
Test group:LC+LCBDE+T-tube drainage

Sponsors

Subei People's Hospital of Jiangsu province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who successfully implemented LCBDE in Subei people's Hospital of Yangzhou City from January 2023 to June 2025 have signed informed consent. Choledocholithiasis was diagnosed before operation and the diameter of common bile duct dilatation was greater than or equal to 10 mm. It can be complicated with cholecystolithiasis and / or hepatolithiasis. There may be a history of two or more biliary surgery. Patients with primary suture of bile duct or T-tube drainage after choledocholithotomy.

Exclusion criteria

Exclusion criteria: LCBDE was converted to laparotomy during operation. Change the mode of operation such as choledochojejunostomy during operation. Preoperative complicated with pancreatitis, Mirizzi syndrome, acute obstructive cholangitis, bile duct or gallbladder cancer, severe pulmonary heart disease. Those who have contraindications for general anesthesia.

Design outcomes

Primary

MeasureTime frame
Operation time;Intraoperative bleeding volume;

Secondary

MeasureTime frame
Postoperative complication;

Countries

China

Contacts

Public ContactPeng Xu

Subei People's Hospital of Jiangsu province

pengxu1986@126.com18952578176

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026